A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

← catalyst calendar

NCT05929066

Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.

Phase

Phase 3

Status

Completed

Study type

Interventional

Design

Randomized · Double · Treatment

Enrollment

2,335actual

Sites

134

Countries

Australia, Brazil, Canada +9

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-07-10

actual

When the study began enrolling

Primary completion

2026-04-06

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2026-04-30

actual

The whole study's end, after follow-up

First posted

2023-07-03

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-03

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Obesity
Overweight
Osteoarthritis, Knee
Obstructive Sleep Apnea

Interventions

Drug: Retatrutide — also filed as LY3437943
Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Percent Change From Baseline in Body Weight

measured Baseline, Week 80

Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score for GOA1 Subset

measured Baseline, Week 80

Change from Baseline in Apnea-Hypopnea Index (AHI) Events Per Hour for GSA1 Subset

measured Baseline, Week 80

Percent Change from Baseline in Body Weight to

measured Baseline, Week 104

Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed